COVID-19 mRNA vaccines increase risk of cardiac-related death: Florida Surgeon General

Dr. Joseph A Ladapo, Surgeon General of Florida, advised against obtaining mRNA COVID-19 vaccines on Saturday (local time), citing an increased risk of cardiac-related death.

“Today, we published an analysis on COVID-19 mRNA vaccinations that the public should be aware of.” This study discovered an elevated risk of cardiac-related death in men aged 18 to 39. FL will not be mute on the truth, according to Ladapo.

The Florida Department of Health (Department) conducted an analysis through a self-controlled case series, which is a technique originally developed to evaluate vaccine safety. This studied mortality risk following mRNA COVID-19 vaccination.

This analysis found an 84 per cent increase in the relative incidence of cardiac-related death among males 18-39 years old within 28 days following mRNA vaccination, read an advisory of Florida Health, signed by Florida Governor Ron DeSantis and Ladapo.

It further advised individuals with pre-existing cardiac conditions, such as myocarditis and pericarditis, to take particular caution when considering vaccination and discuss it with their healthcare provider.

With a high level of global immunity to COVID-19, the benefit of vaccination is likely outweighed by this abnormally high risk of cardiac-related death among men in this age group. Non-mRNA vaccines were not found to have these increased risks, read the Florida Department of Health Bulletin.

“Studying the safety and efficacy of any medications, including vaccines, is an important component of public health,” said Surgeon General Dr Joseph Ladapo.

“Far less attention has been paid to safety and the concerns of many individuals have been dismissed – these are important findings that should be communicated to Floridians,” added Ladapo.

Meanwhile, India’s first mRNA Covid-19 vaccine is likely to be available soon. The Drugs controller general of India (DCGI) is expected to give Emergency Use Authorisation to Gennova’s mRNA vaccine soon.

The company has conducted phase 2 and phase 3 data trials on 4000 participants to evaluate vaccine safety, immunogenicity and tolerability.

The vaccine – GEMCOVAC-19 – is the country’s first homegrown mRNA COVID- 19 vaccine.

According to officials at Gennova, the trial data showed that the vaccine was safe and well-tolerated. Immunogenicity measured at 2 weeks post-dose showed that GEMCOVAC-19 is non-inferior to Covishield.

The two-dose vaccine will have to be administered intramuscularly, 28 days apart.

As the Covid-19 pandemic spread, an mRNA vaccine candidate was the first to enter human trials globally. The first two vaccines that were made available for use in the US were based on mRNA technology.

Unlike vaccines that put a weakened or inactivated virus in your body to activate an immune response, these two Covid-19 vaccines (Pfizer-BioNTech and Moderna) used messenger RNA or mRNA to deliver a message to your immune system.

Essentially, the method use genetically modified mRNA to direct cells to produce the S-protein present on the surface of the Covid-19 virus. According to the Mayo Clinic in the United States, after vaccination, muscle cells begin producing S-protein fragments and displaying them on cell surfaces. As a result, the body produces antibodies.

Also Read: Quick OPD registrations now possible under Ayushman Bharat Digital Mission